Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Dylan Dupuis has reinstated a Buy rating on Chemomab Therapeutics (NASDAQ:CMMB) with a maintained price target of $7.
December 19, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Dylan Dupuis reinstated a Buy rating on Chemomab Therapeutics with a price target of $7, indicating a positive outlook for the stock.
The reinstatement of a Buy rating by a reputable analyst typically signals confidence in the company's prospects, which can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100